ESMO 2025: Prostate highlights

ESMO 2025: Renal highlights

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings